News Photo

Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100

Bold Therapeutics announced that the first patient for the company’s Phase 1b clinical trial has been enrolled at the Cross Cancer Institute.

Read more
Post Photo


BOLD-100 Shows Inhibition of DNA Repair Pathways in Breast Cancer

Georgetown University has recently published a new manuscript showing that Bold Therapeutics’ BOLD-100 has anti-cancer potential in breast cancer.

Post Photo


BOLD-100 Significantly Outperforms Remdesivir Head-to-Head in SARS-CoV-2 (COVID-19) Model

Bold Therapeutics recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral.

Post Photo


BOLD-100 Demonstrates Nanomolar Range Inhibition of Live COVID-19 In Vitro

Bold Therapeutics has in vitro data showing that its lead clinical-stage therapeutic, BOLD-100, successfully inhibits live SARS-CoV-2 (COVID-19).

Post Photo


 Bold Therapeutics Expands COVID-19 Consortium 

Bold Therapeutics is excited to expand its COVID-19 consortium to include four additional collaborators from prominent institutions in Canada and the U.K.

Post Photo


Bold Therapeutics and Hana Pharm Execute Option Agreement for Exclusive Development and Commercialization Rights to BOLD-100 in South Korea

Bold Therapeutics announced it has executed an option agreement with Hana Pharm Co. for BOLD-100 in South Korea.

Post Photo


Bold Therapeutics and the University of Ottawa Initiate Research Partnership to Study BOLD-100 in the Treatment of COVID-19

Bold Therapeutics announced a research partnership with the University of Ottawato to explore the potential utility of BOLD-100 as a novel antiviral agent.

Post Photo


Bold Therapeutics Seeks Collaborators for Rapid Development of BOLD-100; Lead Drug Candidate Has Potential Utility in the Treatment of COVID-19

Bold Therapeutics announced that recent developments have suggested the potential utility of its lead drug BOLD-100 as a novel antiviral agent.

Post Photo


Bold Therapeutics to Initiate Phase 1b Trial of BOLD-100 in GI Cancers

Bold Therapeutics announced that it has received clearance from Health Canada to initiate a Phase 1b trial.

Post Photo


Bold Therapeutics Visiting Collaborators in Europe

Bold Therapeutics will be visiting with multiple collaborators, vendors and partners in Europe from March 2nd to 6th.